Rationale and Dose Regimen for Sitagliptin/ Glimepiride Combination Therapy in Type 2 Diabetes Treatment

Abstract

This study explores how glimepiride, alone or in combination with sitagliptin, affected glycemic control in
Type 2 diabetes patients. Type 2 diabetes was induced in rats by feeding them a high-fat diet and injecting
them with Alloxan and nicotinamide. Forty-two rats were divided equally into seven groups. Negative
control and group 2-7: rats fed with the HFD Positive control (diabetic non-treated) Group (T1, T2, T3, T4
and T5) were treated with monotherapy and combination. All the treatment regimen reduces fasting blood
glucose and enhanced GLP-1 and insulin level as indicated by an increase in the area under the curve.
Additionally, as opposed to monotherapies, the combination category had better glycemic regulation. As a
result, we assume that sitagliptin/glimepiride combined therapy has a synergistic effect.